Shopping Cart 0
Cart Subtotal
USD 0

Benign Prostatic Hyperplasia - Pipeline Review, H2 2018

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Benign Prostatic Hyperplasia-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia-Pipeline Review, H2 2018, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Benign Prostatic Hyperplasia (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 9, 4, 5, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Benign Prostatic Hyperplasia (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).

- The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Benign Prostatic Hyperplasia (Male Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia (Male Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 2

Introduction 5

Benign Prostatic Hyperplasia-Overview 6

Benign Prostatic Hyperplasia-Therapeutics Development 7

Benign Prostatic Hyperplasia-Therapeutics Assessment 15

Benign Prostatic Hyperplasia-Companies Involved in Therapeutics Development 23

Benign Prostatic Hyperplasia-Drug Profiles 33

Benign Prostatic Hyperplasia-Dormant Projects 95

Benign Prostatic Hyperplasia-Discontinued Products 98

Benign Prostatic Hyperplasia-Product Development Milestones 99

Appendix 109


List Of Figure

List of Figures

Number of Products under Development for Benign Prostatic Hyperplasia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Benign Prostatic Hyperplasia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Aphios Corp, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Aquestive Therapeutics Inc, H2 2018

Benign Prostatic Hyperplasia-Pipeline by ASKA Pharmaceutical Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by BCWorld Pharm Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Biolab Farmaceutica Ltda, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Curadis GmbH, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by GemVax & KAEL Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Health Ever Bio-Tech Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Jeil Pharmaceutical Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Kissei Pharmaceutical Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Meiji Seika Pharma Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Mezzion Pharma Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Nymox Pharmaceutical Corp, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Ono Pharmaceutical Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by OPKO Health Inc, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Sophiris Bio Inc, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by XuanZhu Pharma Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Yuyu Pharma Inc, H2 2018

Benign Prostatic Hyperplasia-Dormant Projects, H2 2018

Benign Prostatic Hyperplasia-Discontinued Products, H2 2018

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Benign Prostatic Hyperplasia Therapeutic Products under Development, Key Players in Benign Prostatic Hyperplasia Therapeutics, Benign Prostatic Hyperplasia Pipeline Overview, Benign Prostatic Hyperplasia Pipeline, Benign Prostatic Hyperplasia Pipeline Assessment


Companies

Aphios Corp

Aquestive Therapeutics Inc

ASKA Pharmaceutical Co Ltd

BCWorld Pharm Co Ltd

Biolab Farmaceutica Ltda

Chong Kun Dang Pharmaceutical Corp

Curadis GmbH

Dongkook Pharmaceutical Co Ltd

GemVax & KAEL Co Ltd

GeneScience Pharmaceuticals Co Ltd

Health Ever Bio-Tech Co Ltd

Jeil Pharmaceutical Co Ltd

Kissei Pharmaceutical Co Ltd

Meiji Seika Pharma Co Ltd

Mezzion Pharma Co Ltd

Nymox Pharmaceutical Corp

Ono Pharmaceutical Co Ltd

OPKO Health Inc

Sophiris Bio Inc

Sun Pharma Advanced Research Company Ltd

XuanZhu Pharma Co Ltd

Yuyu Pharma Inc

Benign Prostatic Hyperplasia-Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Benign Prostatic Hyperplasia-Pipeline Review, H2 2018, provides an overview of the Benign Prostatic Hyperplasia (Male Health) pipeline landscape.

Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a small gland that encircles the urethra in males and produces a fluid that makes up part of semen. Symptoms include decreased strength of the urine stream, dribbling after urination, pain during urination, waking at night to urinate, difficulty starting a urine stream. Treatment options for BPH include surgery and medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Benign Prostatic Hyperplasia-Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Benign Prostatic Hyperplasia (Male Health) pipeline guide also reviews of key players involved in therapeutic development for Benign Prostatic Hyperplasia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 9, 4, 5, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Benign Prostatic Hyperplasia (Male Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Benign Prostatic Hyperplasia (Male Health).

- The pipeline guide reviews pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Benign Prostatic Hyperplasia (Male Health) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Benign Prostatic Hyperplasia (Male Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Benign Prostatic Hyperplasia (Male Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Benign Prostatic Hyperplasia (Male Health).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Benign Prostatic Hyperplasia (Male Health) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Scope

Table of Contents

Table of Contents 2

Introduction 5

Benign Prostatic Hyperplasia-Overview 6

Benign Prostatic Hyperplasia-Therapeutics Development 7

Benign Prostatic Hyperplasia-Therapeutics Assessment 15

Benign Prostatic Hyperplasia-Companies Involved in Therapeutics Development 23

Benign Prostatic Hyperplasia-Drug Profiles 33

Benign Prostatic Hyperplasia-Dormant Projects 95

Benign Prostatic Hyperplasia-Discontinued Products 98

Benign Prostatic Hyperplasia-Product Development Milestones 99

Appendix 109


List Of Figure

List of Figures

Number of Products under Development for Benign Prostatic Hyperplasia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018


List Of Table

List of Tables

Number of Products under Development for Benign Prostatic Hyperplasia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Aphios Corp, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Aquestive Therapeutics Inc, H2 2018

Benign Prostatic Hyperplasia-Pipeline by ASKA Pharmaceutical Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by BCWorld Pharm Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Biolab Farmaceutica Ltda, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Curadis GmbH, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by GemVax & KAEL Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Health Ever Bio-Tech Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Jeil Pharmaceutical Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Kissei Pharmaceutical Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Meiji Seika Pharma Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Mezzion Pharma Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Nymox Pharmaceutical Corp, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Ono Pharmaceutical Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by OPKO Health Inc, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Sophiris Bio Inc, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by XuanZhu Pharma Co Ltd, H2 2018

Benign Prostatic Hyperplasia-Pipeline by Yuyu Pharma Inc, H2 2018

Benign Prostatic Hyperplasia-Dormant Projects, H2 2018

Benign Prostatic Hyperplasia-Discontinued Products, H2 2018

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Benign Prostatic Hyperplasia Therapeutic Products under Development, Key Players in Benign Prostatic Hyperplasia Therapeutics, Benign Prostatic Hyperplasia Pipeline Overview, Benign Prostatic Hyperplasia Pipeline, Benign Prostatic Hyperplasia Pipeline Assessment


Companies

Aphios Corp

Aquestive Therapeutics Inc

ASKA Pharmaceutical Co Ltd

BCWorld Pharm Co Ltd

Biolab Farmaceutica Ltda

Chong Kun Dang Pharmaceutical Corp

Curadis GmbH

Dongkook Pharmaceutical Co Ltd

GemVax & KAEL Co Ltd

GeneScience Pharmaceuticals Co Ltd

Health Ever Bio-Tech Co Ltd

Jeil Pharmaceutical Co Ltd

Kissei Pharmaceutical Co Ltd

Meiji Seika Pharma Co Ltd

Mezzion Pharma Co Ltd

Nymox Pharmaceutical Corp

Ono Pharmaceutical Co Ltd

OPKO Health Inc

Sophiris Bio Inc

Sun Pharma Advanced Research Company Ltd

XuanZhu Pharma Co Ltd

Yuyu Pharma Inc